Kidney Week

Abstract: FR-PO1089

Urinary Soluble CD163 as a Biomarker for Lupus Nephritis

Session Information

• Glomerular Diseases: Clinical, Outcomes, Trials - II
  October 26, 2018 | Location: Exhibit Hall, San Diego Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Glomerular Diseases

• 1203 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

• Suwa, Junya, Gunma University Graduate School of Medicine, Maebashi, Japan

Junya Suwa,

• Ikeuchi, Hidekazu, Gunma University Graduate School of Medicine, Maebashi, Japan

Hidekazu Ikeuchi,

• Kajiyama, Hiroshi, Saitama Medical University, Saitama, Japan

Hiroshi Kajiyama,

• Hamatani, Hiroko, Gunma University Graduate School of Medicine, Maebashi, Japan

Hiroko Hamatani,

• Nakasatomi, Masao, Gunma University Graduate School of Medicine, Maebashi, Japan

Masao Nakasatomi,

• Kaneko, Yoriaki, Gunma University Graduate School of Medicine, Maebashi, Japan

Yoriaki Kaneko,

• Sakairi, Toru, Gunma University Graduate School of Medicine, Maebashi, Japan

Toru Sakairi,

• Nojima, Yoshihisa, Japan Red Cross Maebashi Hospital, Maebashi, Japan

Yoshihisa Nojima,

• Hiromura, Keiju, Gunma University Graduate School of Medicine, Maebashi, Japan

Keiju Hiromura,

• Mimura, Toshihide, Saitama Medical University, Saitama, Japan

Toshihide Mimura,

Background

Recently, it has been reported that urinary soluble CD163 (UsCD163) reflects glomerular inflammation of ANCA-associated nephritis and lupus nephritis (LN). We examined the significance of UsCD163 as a biomarker for histological activity and treatment response of LN.

Methods

We investigated the levels of UsCD163 before and after treatment in 52 LN patients (49 females, median age 37 years old) who were diagnosed as ISN/RPS Class III, IV or V and treated for LN since 2010 to 2015 in Gunma University and Saitama Medical University hospitals by ELISA. We also examined whether UsCD163 could be a predictor of remission of LN.

Results

RESULTS: Levels of UsCD163/creatine (Cr) were higher in Cass IV and Class V compared to Class III: III, 2.55 (1.40-5.55); IV, 8.84 (3.05-19.1); V, 8.10 (7.14-10.3) ng/mgCr;, median, (IQR). Significant correlations were observed between levels of UsCD163/Cr and urinary protein/Cr or systemic lupus erythematosus disease activity index (SLEDAI) score, but not eGFR (r=0.421, p=0.0026; r=0.465, p<0.001; r=-0.212, p=0.143). Associations between UsCD163/Cr and histological parameters were shown in Table 1. Significant positive correlations were found between levels of UsCD163/Cr and activity index, leukocyte infiltration or cellular crescents. UsCD163/Cr levels rapidly decreased after treatments. Receiver operating characteristic analysis showed UsCD 163/Cr >17.3 ng/mgCr before treatment was predictor of the presence of cellular crescent (sensitivity 85%, specificity 44%). UsCD163/Cr <3.0 ng/mgCr before treatment was a predictive marker for early proteinuria remission defined as urine protein/Cr <0.3 g/gCr at 3 months after treatment (sensitivity 42%, specificity 92%, positive predictive value 92%, negative predictive value 69%).

Conclusion

UsCD163 could be a potential biomarker for histological activity and treatment response of LN.

Table 1. Correlation between UsCD163/Cr and histological parameters

Funding

• Government Support - Non-U.S.